SEC Tracker
Get the app
ADMA · XBRL financial data

Adma Biologics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ADMA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers67,27573,904*81,875107,191119,839117,549*114,802121,984134,224139,163*114,493124,395
Cost of revenue42,62242,817*42,76749,73860,18054,216*53,70554,75758,59850,347*33,74338,118
Gross profit24,65331,086*39,10857,45359,65963,333*61,09767,22775,62688,816*80,75086,277
Research and development596445*450560412391*8261,0311,5281,376*2,5976,014
Selling, general and administrative14,72615,535*15,63916,60818,56023,317*24,07922,21421,77623,512*26,74226,737
Total operating expenses15,96716,853*17,28718,25220,02125,010*26,21624,42924,61426,065*22,47633,832
Operating income (loss)8,68514,233*21,82139,20139,63838,323*34,88142,79851,01262,751*58,27452,445
Interest income423612*384449666598*608400376487*——
Interest expense6,3986,215*3,7693,7833,4992,879*1,9751,8341,6751,626*2,1003,424
Other income (expense)(146)(101)*(35)(16)(56)(86)*(64)(108)(21)(17)*(140)(22)
Income tax expense (benefit)00*5953,789840(77,183)*6,5465,87811,08712,216*11,79912,415
Net income (loss)2,565(17,645)*17,80632,06235,909111,896*26,90434,21936,42849,379*45,32837,822
Earnings per share, basic USD per share0.01(0.08)*0.080.140.150.47*0.110.140.150.21*0.190.17
Earnings per share, diluted USD per share0.01(0.08)*0.080.130.150.45*0.110.140.150.20*0.190.16
Weighted average shares, basic thousands of shares225,277225,968*228,875232,418234,571236,420*237,775241,491238,603235,350*236,073228,233
Weighted average shares, diluted thousands of shares233,761217,484*236,414242,167244,804249,896*244,676248,608244,664241,705*239,956230,337

Balance sheet

CSV

Fiscal quarters (ADMA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents74,15751,35245,32588,24486,707103,14771,62590,28561,38587,630138,153136,020
Accounts receivable31,31927,42149,62130,11350,14049,99999,412109,726137,673158,429135,862138,231
Inventory163,116172,906177,732179,810171,801170,235172,188191,464196,667206,465222,098239,313
Prepaid and other current assets5,1075,3343,7415,5249,5458,0298,5898,0886,9307,45815,06014,639
Total current assets273,699257,013276,419303,691318,193331,410351,814399,563402,655466,512511,173528,203
Property and equipment, net54,81553,83555,31754,32653,69454,70757,71057,50169,50965,05765,01066,664
Right-of-use asset9,7549,6359,3979,1528,8978,6348,0208,9619,2716,6506,4026,146
Goodwill3,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,5303,530
Total assets348,997329,182350,875376,399390,618488,678510,569558,380568,687624,242665,184684,210
Accounts payable10,85115,66017,18614,17916,02020,21920,60729,76924,02122,51920,52331,724
Current portion of long-term debt—————0——2,3442,8133,2813,750
Total current liabilities41,84149,80653,08844,17744,89155,54253,49874,94156,49069,54173,54175,757
Long-term debt—————72,337——70,08469,330193,584192,839
Lease liability, non-current9,9659,7799,4879,1828,8658,5618,2989,3019,3976,6466,3656,072
Total liabilities197,559193,976197,169188,130158,728139,660137,150160,055137,501146,922274,859276,002
Accumulated deficit(488,611)(506,256)(488,450)(456,388)(420,479)(308,583)(281,679)(247,460)(211,032)(161,653)(116,325)(78,503)
Total stockholders' equity151,437135,206153,706188,269231,890349,018373,419398,325431,186477,320390,325408,208
Total liabilities and equity348,997329,182350,875376,399390,618488,678510,569558,380568,687624,242665,184684,210
Common shares outstanding (cover page) thousands of shares225,968228,220231,809233,083236,390237,615238,734238,631237,998238,159231,773223,985

Cash flows

CSV

Fiscal quarters (ADMA's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)2,565(17,645)*17,80632,06235,909111,896*26,90434,21936,42849,379*45,32837,822
Stock-based compensation1,6951,745*2,1412,8633,1795,433*4,6244,9635,0475,392*6,3296,135
Depreciation and amortization1,9001,900*1,9001,9001,9002,000*1,9002,0002,0002,000*1,8001,700
Net cash from operating activities11,985*17,596*(2,218)45,646*25,028*50,216*(19,675)21,139*13,293*35,639*58,24929,539*
Purchases of property and equipment757*1,197*2,3472,066*1,056*2,757*4,7012,422*14,368*1,084*2,5432,256*
Net cash from investing activities(757)*(1,407)*(2,362)(2,365)*(1,098)*(2,750)*(4,720)(2,527)*(14,368)*(276)*2,404(2,256)*
Proceeds from issuing common stock—year only———year only——————
Share repurchases—year only———0*00*23,038*8,902*130,19125,054*
Net cash from financing activities415*(38,994)*(1,447)(362)*(25,467)*(31,026)*(7,127)48*(27,825)*(9,118)*(10,130)(29,416)*
Net change in cash11,644*(22,805)*(6,027)42,919*(1,537)*16,440*(31,522)18,660*(28,900)*26,245*50,523(2,133)*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Adma Biologics136,020124,39529,539*224.0M— 10-QJun 30, 2026
Lantheus Holdings593,298388,18092,203*65.3M— 10-QJun 30, 2026
Soleno Therapeutics133,026not reported25,98052.1M— 10-QMar 31, 2026
Axsome Therapeutics313,859259,691(9,469)*52.6M14.7 quarters 10-QSep 30, 2026
Halozyme Therapeutics163,138480,999240,891*113.5M— 10-QJun 30, 2026
Alkermes631,314480,13293,477*168.0M— 10-QSep 30, 2026
Rhythm Pharmaceuticals39,98192,128(3,062)*69.3M16.9 quarters 10-QSep 30, 2026
Vaxcyte183,190not reported(232,471)*148.8M6.4 quarters 10-QJun 30, 2026
PERRIGO399,7001,022,80082,600*138.8M— 10-QJun 27, 2026

Not investment advice. Not affiliated with the U.S. SEC.